Gamma aminobutyric acid (GABA) or -aminobutyrate, is the major inhibitory neurotransmitter in the central nervous system. GABA is produced from the amino acid glutamate through the action of the enzyme glutamate decarboxylase, and is inactivated by degradation to succinate in a two step mechanism involving the enzymes GABA-glutamate transaminase and succinate semialdehyde dehydrogenase.
GABAA is the most prominent. Many medications, many neuroactive drugs (see Chapters 16 and 22), "benzodiazepines, barbiturates, ethanol, anesthetic steroids, and volatile anesthetics", act on the GABAA receptor.
GABAB "function as autoreceptors, inhibiting GABA release".
GABAC is less widely distributed and is in the retina, spinal cord, superior colliculus, and pituitary gland. GABAC receptors are not affected by the agonist baclofen or the modulators benzodiazepines and barbiturates.
Role in clinical pharmacology
GABA modulators have various roles.
Gamma-aminobutyric acid (GABA) (physiologic) agonists
(may not relate to duration of effect)
|short (< 6 hrs)||midazolam (1-4 hrs)
triazolam (1.5-5.5 hrs)
oxazepam (2.8-5.7 hrs)
|zolpidem (2 hrs)|
zopiclone (5-6 hrs)
|intermediate (6 - 24 hrs)||alprazolam|
|long (> 24 hrs)||chlordiazepoxide|
Drugs that increase the effect or secretion of GABA are called GABAergic, such as baclofen.
Many sedatives work by increasing receptiveness of GABAA receptors.
Gabapentin & Pregabalin
Nonselective BZ1 and BZ2 agonists
Benzodiazepines are also nonselective GABAergic by increasing receptiveness of the GABAA receptors. However, benzodiazepines do this by increasing the frequency of openings of channels in the cell membrane.
Benzodiazepine receptors are BZ1 and BZ2.
BZ1 selective agonists
Cyclopyrrolones / Piperazines
- Zolpidem (Ambien)
- Katzung, Bertram G. (2006). Basic and clinical pharmacology. New York: McGraw-Hill Medical Publishing Division. ISBN 0-07-145153-6.
- Bloom Floyd E, "Chapter 12. Neurotransmission and the Central Nervous System" (Chapter). Brunton LL, Lazo JS, Parker KL: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11e: http://www.accessmedicine.com/content.aspx?aID=937279.
- Charney Dennis S, Mihic S. J, Harris R. A, "Chapter 16. Hypnotics and Sedatives" (Chapter). Brunton LL, Lazo JS, Parker KL: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11e:.
- Rush CR, Frey JM, Griffiths RR (1999). "Zaleplon and triazolam in humans: acute behavioral effects and abuse potential.". Psychopharmacology (Berl) 145 (1): 39-51. PMID 10445371. >